StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
VRDNViridian Therapeutics, Inc.\DE
stockpulse.co.kr
Nasdaq
$22.37▼ 0.02%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.47BShares out 1.100M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

7
  • 8.21Overnight26.08.21 09:05
    4Ownership#●●●#●●●

    Viridian Therapeutics, Inc.\DE

    Jennifer Tousignant, an executive at Viridian Therapeutics, filed an SEC Form 4 on August 20, 2026, reporting changes in beneficial ownership of company securities as of August 19, 2026. This filing serves as a standard disclosure of insider stock holdings and transactions.…more

    $22.37-0.02%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 8.20After-hours26.08.21 05:14
    SCHEDULE 13GOwnership

    Viridian Therapeutics, Inc.\DE

    Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen have filed a joint acquisition statement regarding their stake in Viridian Therapeutics (VRDN). The parties entered into a joint filing agreement on August 20, 2026, to report their collective beneficial ownership via Schedule 13G.…more

    $22.37-0.02%vs prev close
    View filingShare
  • 8.19Regular26.08.20 03:30
    144Ownership

    Viridian Therapeutics, Inc.\DE

    Jennifer Tousignant, an executive at Viridian Therapeutics, has filed a Form 144 to report a proposed sale of company securities. This filing serves as a formal notification of the insider's intention to dispose of shares.…more

    $22.37-0.02%vs prev close
    View filingShare

6 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 10.16Regular26.10.16 23:13
    Bullish#●●●#●●●

    Roche Secures FDA Approval for First At-Home Thyroid Eye Disease Therapy…more

    Roche's Enspryng has received FDA approval as the first at-home subcutaneous treatment for thyroid eye disease. The drug demonstrated significant clinical efficacy in reducing proptosis and double vision in Phase 3 trials.…more

    $22.37-0.02%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga